DIVISLAB2020-04-012020-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member DIVISLAB2020-04-012020-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares DIVISLAB 2020-04-01 2021-03-31 2020-07-29 INR Lakhs First quarter Single segment Pharmaceuticals 2020-04-01 2020-06-30 Unaudited Consolidated 17304700000.00 173300000.00 17478000000.00 4642700000.00 37900000.00 1717800000.00 1839000000.00 2300000.00 562000000.00 2066500000.00 10868200000.00 6609800000.00 0.00 6609800000.00 1878500000.00 -189300000.00 1689200000.00 0.00 4920600000.00 0.00 0.00 0.00 0.00 4920600000.00 400000.00 4921000000.00 4920600000.00 0.00 400000.00 0.00 530900000.00 2 18.54 18.54 0.00 0.00 18.54 18.54 1. Statement of Consolidated Unaudited Financial Results for the quarter ended 30.06.2020¿(Statement) is prepared in accordance with IndAS prescribed under Sec133 of the Companies Act, 2013 and in terms of Reg 33 of the SEBI LODR Regulations, 2015 as amended. The Statement is, as reviewed by the Audit Committee, considered and approved by the Board of Directors of the Company at its meeting held on 8.08.2020.Statement is subjected to limited review by the Auditors and their report contains no qualification.2¿The Consolidated unaudited financial results include the unaudited financial results of Divi¿s Laboratories Limited and its subsidiaries Divis Laboratories (USA) Inc. and Divi¿s Laboratories Europe AG.3 Group is engaged in the manufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients; and the same constitutes a single reporting business segment as per Ind AS108.¿4 The Group does not have any discontinued operations and the Profit for the period represents the Profits from continuing operations only.¿5¿Current tax expense includes adjustment of tax reversals of earlier years amounting to Rs. 665 lakhs.¿6 Group has not experienced any significant impact on its operations, supply chain and recoverability of carrying amounts of financial and non-financial assets due to COVID19 pandemic. As the pandemic continues to evolve, Group will continue to closely monitor for any material changes to future economic conditions.7¿Forex gain included in Other income/(loss) included in Other expenses for the respective periods is as given below(Rs in lakhs)-Quarter Ended-30.06.2020-Rs.481,¿1.03.2020-Rs.5710,30.06.2019-Rs.(612),Year Ended-31.03.2020 Rs8211.8.Figures for the quarter ended 31.03.2020 are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figures up to the third quarter of the respective financial year.9¿Amount is below the rounding norm adopted by the Group.